Navigation Links
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
Date:5/20/2009

NANTONG CITY, China, May 20 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to provide an update on the Company's progress to date this year and guidance on its projected financial performance for the balance of 2009.

Financial Highlights:

  • In Q1 2009, the Company's total revenue increased to RMB 4.60 million (US $0.68 million), representing a 127 percent increase year-over-year from the same period in 2008, when total sales were RMB 2.0 million (US $.29 million).
  • Also in Q1, the Company signed sales contracts for a total 1.5 millions units for Cisatracurium Besylate, Sinobiopharma's flagship drug, with business agents who distribute the Company's products in 30 provinces and key major cities throughout China. Total turnover is projected to be more than RMB 105 million (US $15.3 million), of which 70 percent will be Sinobiopharma profit.

Sales, Production and Marketing Highlights:

  • Sales of Cisatracurium Besylate increased by more than 200 percent from 2007 to 2008. Sales of 1.5 million units are projected in 2009. Sinobiopharma's patented formulation of Cisatracurium Besylate is now China's top-selling pre-surgical skeletal muscle relaxant.
  • Sales of Clindamycin, an antibiotic, increased by 150 percent from 2007 to 2008. Sales of 1 million units are projected in 2009.
  • The Company is currently in the process of launching in the domestic Chinese market. Sinobiopharma's formulation of this antihypertensive is the world's first in capsule form, making it easier to swallow. Sales of more than 500,000 capsules are projected in 2009. As the first Chinese maker of the latest generation of this drug, the Company's has multiple competitive advantages, including lower cost of active pharmaceutical ingredients (API), the ca
    '/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
8. SemBioSys updates Apo AI development program
9. Strategic Diagnostics Updates Roth Conference Presentation Time
10. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
11. SGX Pharmaceuticals Updates Date of Presentation at the BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... de septiembre de 2014  Cryoport, Inc. ... mundial de soluciones logísticas avanzadas criogénicas para ... vida, anunció hoy la contratación de Broekman ... sede en Rótterdam, Países Bajos, para proporcionar ... en rápido crecimiento. Según los términos del ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Global Products, BASINGSTOKE, England, October 8 ... global specialty biopharmaceutical,company, announces that it has agreed ... Almirall for a cash consideration of $213m. The ... sodium),and VANIQA(R) (eflornithine hydrochloride), and six other non-promoted,products1 ...
... about the origins of quantum dot blinking, researchers ... Laboratory, the University of Chicago and the California ... characterize it on faster time scales than have ... also known as quantum dots, are being intensively ...
... to Vice President, Research Operations ... Non-Profit Foundation, CARLSBAD, Calif., Oct. 5 ... focused on the discovery and,development of small-molecule therapeutics ... diseases, today announced changes to its,research management. Dr. ...
Cached Biology Technology:Shire Divests Non-Core Product Portfolio to Almirall 2Shire Divests Non-Core Product Portfolio to Almirall 3Argonne researcher studies what makes quantum dots blink 2Ardea Biosciences Announces Changes to Research Management 2Ardea Biosciences Announces Changes to Research Management 3
(Date:9/17/2014)... R.I. [Brown University] After decades of decline, grasses ... saltmarshes. To the eye, the marsh in those places ... that a key service of the marsh coastal ... back but the ecosystem function hasn,t come back," said ... senior author of the study in the journal ...
(Date:9/17/2014)... been growing significantly faster since the 1960s. The typical ... but they have accelerated -- by as much as ... carried out by scientists from Technische Universitt Mnchen based ... been continuously observed since 1870. Their findings were published ... ago, "forest dieback" was a hot topic, with the ...
(Date:9/17/2014)... United Kingdom forms a new crime unit designed to ... last year over horse meat being passed off as ... for detecting meat adulteration. They describe their approach, which ... Journal of Agricultural and Food Chemistry . , ... a major global economic problem. But they also say ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... University of Delaware have developed a "smart" hydrogel that can ... Over the past few decades, smart hydrogels have been created ... "The idea of a smart hydrogel that can release ... professor of materials science and engineering and biomedical engineering. "What,s ...
... Living organisms have adapted to the day-night cycle and, in ... are not completely known yet but its functioning has been ... of normal circadian rhythms can have deleterious effects on health; ... the time of feeding was shown to affect the ability ...
... of the white-throated sparrow has identified a biological pathway connecting ... wild to variation in their genome. The Proceedings ... is publishing the results of the experiments, conducted by the ... Psychology. The research, which comprised behavioral observations ...
Cached Biology News:UD-developed smart gels deliver medicine on demand 2The internal clock and feeding rhythm set the pace of the liver 2Wild sparrow study traces social behaviors in the field to specific gene 2Wild sparrow study traces social behaviors in the field to specific gene 3Wild sparrow study traces social behaviors in the field to specific gene 4
... Anti-Natural Killer Cell Receptor-P1, ... Immunogen: Hybridoma produced ... from BALB/c mice immunized (BALB/c ... (LAK) cells and mouse myeloma ...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: